Skip to main content

testosterone cypionate

Generic: TESTOSTERONE CYPIONATE·Brand: AZMIRO, DEPO-TESTOSTERONE, TESTOSTERONE CYPIONATE

testosterone cypionate: 6 clinical trials tracked.

testosterone cypionate evidence translation

What we can confirm

6 tracked trials

No verified listed developer

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about testosterone cypionate, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence5 indications · 4 study sponsors
Clinical Trials (6)

A Multisite, Double-blind, Randomized Controlled Trial Comparing Body Composition, Muscle, and Bone Changes to TestosteRone Therapy With or Without Finasteride After Spinal Cord Injury: TRT-SCI Trial

NCT07742553·Phase 2/Phase 3·GHRS
Not yet recruiting

Primary endpoint: Change in lower limb fat-free mass

InterventionalRandomizedquadruple300 targetStarted 2027-10Completion 2032-034 sites · United StatesVA Office of Research and Development

A Phase II Study of Sequential Bipolar Androgen Therapy and ZEN-3694 in Sequence With Enzalutamide + ZEN-3694 in Asymptomatic Patients With Metastatic CRPC: The COSMYC Trial (COmbined Suppression of MYC)

NCT06922318·Phase 2·KYNB
Recruiting

Primary endpoint: Clinical/radiographic progression free survival (PFS) with BATZEN

Interventionalopen50 targetStarted 2025-08Completion 2031-081 site · United StatesSidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Bipolar Androgen Therapy in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

NCT06305598·Phase 1·RPRX
Recruiting

Primary endpoint: Androgen receptor (AR) activity

Interventionalopen14 targetStarted 2024-12Completion 2027-121 site · United StatesRoswell Park Cancer Institute

Repeat Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Asymptomatic Patients With Metastatic Castration-Resistant Prostate Cancer: The APEX (Androgen and Polyamine Elimination Alternating With Xtandi) Trial

NCT06059118·Phase 2
Recruiting

Primary endpoint: PSA response rate at Cycle 1 Day 64

Interventionalopen50 targetStarted 2023-10Completion 2029-111 site · United StatesSidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Extreme Bipolar Androgen Therapy With Darolutamide and Testosterone Cypionate in Patients With Metastatic Castration-Resistant Prostate Cancer (ExBAT Trial)

NCT04558866·Phase 2·MYOV
Active, not recruiting

Primary endpoint: Rate of Radiographic Progression-Free Survival (rPFS)

Interventionalopen51 targetStarted 2021-06Completion 2026-066 sites · BrazilLatin American Cooperative Oncology Group

A Randomized Phase II Study Comparing Sequential High Dose Testosterone and Enzalutamide to Enzalutamide Alone in Asymptomatic Men With Castration Resistant Metastatic Prostate Cancer

NCT04363164·Phase 2
Recruiting

Primary endpoint: Clinical or Radiographic Progression free survival

InterventionalRandomizedopen150 targetStarted 2020-08Completion 2028-076 sites · United StatesSidney Kimmel Comprehensive Cancer Center at Johns Hopkins